“Never events”, ten hospital-acquired conditions deemed by the Centers for Medicare and Medicaid Services as being reasonably preventable, are rare in patients with bladder cancer who have undergone radical cystectomy.
For patients with bladder cancer, genetic variants in the regulator of G-protein signaling (RGS) pathway are associated with risk, recurrence, progression, and death.
Although low-risk bladder cancer rarely escalates to muscle invasion, patients have a higher risk of disease-specific mortality than the general population.
A urine-based assay “can markedly improve the accuracy” of detecting bladder cancer noninvasively, according to a case-controlled validation study reported during the 2013 Genitourinary Cancers Symposium.
Prediction accuracy up with model of smoking, biomarkers versus clinicopathological variables.
Expression of four microRNAs may serve as potential diagnostic or prognostic biomarkers for bladder cancer.
Among patients with bladder and prostate cancer, MRI enhanced with ultrasmall superparamagnetic particles of iron oxide contrast agent, allows detection of lymph node metastases that are not detected in conventional imaging exams.
Anti-androgen therapies already widely used for prostate cancer may prove to benefit patients with bladder cancer.
No difference in metastasis-free or cancer-specific survival with bladder cancer after median 6.2-year follow-up.
Long-term use of thiazolidinediones increases risk of bladder cancer in persons with type 2 diabetes.
